GHRP-6 vs Tesamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide GH secretagogue that strongly stimulates pituitary GH release via ghrelin receptor activation. It is one of the oldest and most well-studied GHRPs, with a large body of research spanning more than three decades. GHRP-6 produces significant GH pulses but is notable for powerfully stimulating appetite — a side effect that can be beneficial for those in a caloric deficit or disadvantageous for those managing body composition.
Full profileTesamorelin
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved in 2010 as Egrifta, it is the only GHRH peptide with an approved clinical indication — reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy. It has the most robust human trial evidence of any growth hormone secretagogue, including dedicated studies on visceral fat and liver fat.
Full profile| GHRP-6 | Tesamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | Egrifta, Egrifta SV, TH9507, GHRH analog |
| Evidence | Preclinical only | FDA-approved |
| Dosing range | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach | 1.28mg–2mg mg, once daily (subcutaneous) |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection (abdomen, with site rotation) |
| Key side effects | Strong increase in appetite (most common and notable), Elevated cortisol and prolactin at higher doses, Water retention / bloating, Fatigue at high doses | Injection site reactions (erythema, pruritus), Peripheral edema, Arthralgia (joint pain), Myalgia |
| Cited sources | 3 references | 5 references |
Key differences
- Evidence level differs: GHRP-6 is preclinical only, while Tesamorelin is fda-approved.
- Administration: GHRP-6 — Subcutaneous injection, Intramuscular injection; Tesamorelin — Subcutaneous injection (abdomen, with site rotation).
- Dosing units differ: GHRP-6 is dosed in mcg, Tesamorelin in mg — they operate at different scales.
- Frequency: GHRP-6 is typically 1–3 times daily, on an empty stomach; Tesamorelin is once daily (subcutaneous).
- Research depth: this profile cites 3 sources for GHRP-6 vs 5 for Tesamorelin.
How each works
GHRP-6
Human studies confirm GHRP-6 robustly elevates GH within 15–30 minutes of injection, with effects diminishing toward baseline within 2–3 hours. Chronic use increases baseline IGF-1. Research also indicates mild stimulation of cortisol and prolactin, particularly at higher doses. Animal models have shown potential cardioprotective, hepatoprotective, and muscle-sparing effects, though human equivalents are not established.
Tesamorelin
Tesamorelin stimulates pulsatile growth hormone (GH) release from the pituitary, raising serum IGF-1 and preferentially reducing visceral adipose tissue (VAT). FDA-registration trials (Falutz et al., NEJM 2007; JAIDS 2010) showed ~15% VAT reduction versus placebo over 26 weeks. Later randomized trials (Stanley et al., JAMA 2014; Lancet HIV 2019) extended the evidence to liver fat, showing meaningful reductions in hepatic fat fraction and attenuated fibrosis progression in HIV-associated NAFLD.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.